- Deliver a scientifically accurate understanding of what matters most to the Alzheimer's community;
- Match the scope and pace of the development of FDA patient engagement guidance and policies;
- Become a leading representation of patients' voices to inform product and clinical trial design, regulatory submissions, and research, among others.
UsAgainstAlzheimer's recently launched the Alzheimer's Disease Patient and Caregiver Engagement (AD PACE) initiative as a groundbreaking partnership between the public and private sectors to identify and prioritize the needs and preferences of those living with Alzheimer's disease. The organization recently held a webinar to present the AD PACE initiative, which will include leading pharmaceutical companies like Biogen, advocacy organizations like the LEAD Coalition, academic institutions like Alzheimer's Research UK, and federal agency advisers from the National Institutes of Health and the U.S. Food and Drug Administration. AD PACE members will create a new model for bringing the voice of the Alzheimer's community into therapy development and the review process, as well as policymaking and care programs. The AD PACE initiative aims to: